PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 5, 2026British Journal of HaematologyOpen Access

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLaura MonaghanRBRoderick P. BunschotenJBJoana Bittencourt‐Silvestre

Discussion

Loading...

Member takes

Overview

Demonstrates KDM4 targeting reduces cancer cell growth in acute myeloid leukaemia, suggesting new treatment options.

Key Points

  • Investigate the role of KDM4A in acute myeloid leukaemia and explore therapeutic strategies targeting this enzyme.
  • Utilized a novel KDM4 inhibitor based on IOX-1
  • Conducted knockdown using shRNA to target leukaemia cells
  • Analyzed effects on cell viability, cell cycle, and colony formation
  • Evaluated transcriptomic changes related to metabolism and stress response
  • The KDM4 inhibitor induced cell death and arrested the cell cycle in AML cells
  • Colony formation was impaired in treated leukaemia cells
  • Inhibition of KDM4A led to increased double strand DNA breaks
  • KDM4 inhibition sensitized leukaemia cells to PARP inhibitor, olaparib

Cite This Study

Monaghan et al. (2026) studied this question.

synapsesocial.com/papers/698433a5f1d9ada3c1fb0eb2https://doi.org/10.1111/bjh.70351
View Full Paper
Ask AI
Bookmark
Share